Study of sibeprenlimab for children and teens with IgA nephropathy
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine called sibeprenlimab for young people with IgA nephropathy, a kidney disease. The medicine may help reduce protein in the urine and protect kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a kidney biopsy that confirms IgA nephropathy.
- You must be taking a stable dose of blood pressure medicines called ACE inhibitors or ARBs for at least 12 weeks.
- If you are taking a medicine called an SGLT2 inhibitor for IgA nephropathy, you must have been on it for at least 12 weeks.
- Your urine protein level must be at least 0.75 grams per gram of creatinine, measured from three morning urine samples.
- Your kidney function (eGFR) must be at least 30 mL/min/1.73 m².
- You must not have other kidney diseases besides IgA nephropathy, and your blood IgG level must be at least 600 mg/dL.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
This trial enrolls teens and adults with biopsy-proven IgA nephropathy to help doctors learn whether a specific care approach works better for high-quality treatment. It is meant for people whose IgA kidney disease is the primary form (not caused by another illness).
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This trial studies sibeprenlimab to see if it can improve IgA nephropathy, a kidney inflammation condition. You may be able to join if you finished a previous related Otsuka study without major safety problems and your doctor thinks you could benefit.
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.